home / stock / harp / harp articles
Target dose of 12 mg demonstrates robust early activity and manageable tolerability profile:– 63% ORR, 16% cytokine release syndrome (CRS), No I...
Gainers First Wave BioPharma, Inc. (NASDAQ: FWBI) shares jumped 89.5% to $0.8243 after the company announced license agreement for capeserod from ...
Harpoon Therapeutics Inc (NASDAQ: HARP) shares are trading lower after AbbVie Inc (NYSE: ABBV) chose not to exercise its exclusive l...
KOLs to provide insight and discussion of HPN328 targeting SCLC, NEPC and other neuroendocrine tumors Abstract with HPN328 interim data accepted f...
News, Short Squeeze, Breakout and More Instantly...
Harpoon Therapeutics Inc. Company Name:
HARP Stock Symbol:
NASDAQ Market:
Harpoon Therapeutics Inc. Website:
Community Bancorp Inc Vermont (CMTV) is expected to report for Q4 2023 CISO Global, Inc (CISO) is expected to report for Q4 2023 TCTM Kids IT Education Inc. (TCTM) is expected to report for quarter end 2023-12-31 Generation Income Properties Inc. (GIPR) is expected to report for quart...
2024-02-14 02:26:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-01-23 08:45:00 ET On Jan. 8, pharmaceutical giant Merck (NYSE: MRK) moved to acquire biotech Harpoon Therapeutics , (NASDAQ: HARP) for $680 million in cash. The point of the acquisition, which should close in the first half of this year, is to gain access to Harpoon's t...